Effectiveness and safety of Compound Danshen injection as treatment for pregnancy-induced hypertension: A metaanalysis
Purpose: To systematically evaluate the effectiveness and safety of Compound Danshen injection in patients with pregnancy-induced hypertension (PIH).
Methods: PubMed, Embase, Cochrane Library, Chinese biomedical literature database (CBM), VIP (xiAn), China National Knowledge Infrastructure (CNKI) and Wan Fang databases were searched up to March 20, 2018, for all randomized controlled trials (RCTs) on the use of Compound Danshen injection in patients with PIH. Data were extracted from included studies after assessing the quality of literature. Revman 5.3 software was used for statistical analysis．
Results: A total of 18 RCTs involving 1735 patients were included. The results of meta-analysis indicated that the study group was superior to the control group in clinical effectiveness (RR = 1.15, 95 % CI: 1.02 - 1.30); intrauterine fetal distress (RR = 0.26, 95 % CI: 0.09 - 0.70); cesarean section (RR = 0.72, 95 % CI: 0.58 - 0.90), and neonatal asphyxia (RR = 0.23, 95 % CI: 0.11 - 0.48). There were no statistical differences in fetal heart rate abnormalities (RR = 0.58, 95 %, CI: 0.33 - 1.02, p > 0.05) and postpartum hemorrhage (RR = 0.86, 95 % CI: 0.53 - 1.42) between the two groups.
Conclusion: Treatment of PIH with Compound Danshen injection (alone or in combination) is superior to the use of conventional western medical treatment in safety and effectiveness. However, higher quality clinical studies are needed to confirm these results because most trials included in this study were of low quality.
Keywords: Pregnancy-induced hypertension (PIH), Compound Danshen injection, Meta-analysis
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.